Ge Long Hui A P P·2025-10-13 08:58Core Viewpoint - *ST Shuangcheng (002693.SZ) has received marketing approval from the Australian Therapeutic Goods Administration (TGA) for injectable bortezomib, indicating a significant advancement in its product offerings for treating multiple myeloma and mantle cell lymphoma patients [1] Group 1: Product Approval Details - The approved indications for bortezomib include treatment for previously untreated multiple myeloma patients who are unsuitable for high-dose chemotherapy when used in combination with melphalan and prednisone [1] - It is also approved for use in patients under 65 years old with previously untreated multiple myeloma as part of a high-dose chemotherapy regimen combined with autologous stem cell rescue following prior induction therapy [1] - The drug is indicated for patients who have received at least one prior treatment and whose disease has progressed [1] - Additionally, it is approved for adult patients with previously untreated mantle cell lymphoma when used in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone [1]